Gelatinase A-immunoreactive protein in ovarian lesions - Prognostic value in epithelial ovarian cancer

Gynecologic Oncology

Volumn 75, Issue 1, 1999, Pages 91-98

  Westerlund, Anna ^a   Apaja Sarkkinen, Meeri ^a   Höyhtyä, Matti ^b   Puistola, Ulla ^a   Turpeenniemi Hujanen, Taina ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b Diabor Oy   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; GELATINASE A; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; PROTEIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CLASSIFICATION; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYSTADENOMA; EPITHELIUM CELL; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; STAINING;

EID: 0032871733     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5533     Document Type: Article

References (38)

1. Tropé C, Kristensen G. Current status of chemotherapy in gynecologic cancer. Semin Oncol. 5:1997;S15-1-S15-22.
2. Heintz A PM. Cytoreductive surgery. Sharp F, Mason W P, Leake R E. Ovarian Cancer: Biological and Therapeutic Challenges. 1990;157-165 Chapman & Hall, London.
3. Brunner N, Pyke C, Hansen C H, Romer J, Grondahl-Hansen J, Dano K. Urokinase plasminogen activator (uPA) and its type I inhibitor (PAI.1): regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer. Cancer Treat Res. 71:1994;299-309.
4. Sloane B F, Moin K, Lah T T. Regulation of lysosomal endopeptidases in malignant neoplasia. Pretlow T G II, Pretlow T P. Biochemical and Molecular Aspects of Selected Cancers. 1994;411-466 Academic Press, San Diego.
5. Woessner J F Jr. The family of matrix metalloproteinases. Ann N Y Acad Sci. 1994;11-21.
6. Chambers A F, Matrisian L M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 17:1997;1260-1270.
7. Stetler-Stevenson W G. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev. 9:1990;289-303.
8. Liotta L A, Tryggvason K, Garbisa S, Gehron-Robey P, Abe S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 284:1980;67-68.
9. Höyhtyä M, Hujanen E S, Turpeenniemi-Hujanen T, Thorgeirsson U, Liotta L A, Tryggvason K. Modulation of type IV-collagenase activity and invasive behavior of metastatic human melanoma (A2058) cells in vitro by monoclonal antibody to type IV collagenase. Int J Cancer. 46:1990;282-286.
10. Campo E, Tavassoli F A, Charonis A S, Stetler-Stevenson W G, Liotta L A, Merino M J. Evaluation of basement membrane components and the 72 KDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol. 16:1992;500-507.
11. Poulsom R, Hanby A M, Pignatelli M, Jeffery R E, Longcroft J M, Rogers L, Stamp G WH. Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin. J Clin Pathol. 46:1993;429-436.
12. Poulsom R, Pignatelli M, Stetler-Stevenson W G, Liotta L A, Wright P, Jeffery R, Longcroft J M, Rogers L, Stamp G WH. Stromal expression of 72 kDa type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasias. J Pathol. 167S:1992;150A.
13. Pyke C, Ralfkiaer E, Huhtala P, Dano K, Tryggvason K. Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res. 52:1992;1336-1341.
14. Pyke C, Ralfkiaer E, Tryggvason K, Dano K. Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol. 142:1993;359-365.
15. Höyhtyä M, Fridman R, Komarek D, Porter-Jordan K, Stetler-Stevenson W G, Liotta L A, Liang C-M. Immunohistochemical localization of matrix metalloproteinases 2 and its specific inhibitor TIMP-2 in neoplastic tissue with monoclonal antibodies. Int J Cancer. 56:1994;500-505.
16. Naylor M S, Stamp G WH, Davies B, Balkwill F R. Expression and activity of MMPs and their regulators in ovarian cancer. Int J Cancer. 58:1994;50-56.
17. Liabakk N-B, Talbot I, Smith R A, Wilkinson K, Balkwill F. Matrix metalloproteinase 2 (MMP-2) and matrix metalloproteinase 9 (MMP-9) type IV collagenase in colorectal cancer. Cancer Res. 56:1996;190-196.
18. Väisänen A, Tuominen H, Kallioinen M, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol. 180:1996;283-289.
19. Garzetti G G, Ciavattini A, Lucarini G, Goteri G, de Nictolis M, Garbisa S, Masiero L, Romanini C, Graziella B. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications. Anticancer Res. 15:1995;2799-2804.
20. Margulies I MK, Höyhtyä M, Evans C, Stracke M L, Liotta L A, Stetler-Stevenson W G. Urinary type IV collagenase: elevated levels are associated with bladder transitional cell carcinoma. Cancer Epidemiol Biomarkers Prev. 1:1992;467-474.
21. Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Soc (B). 53:1958;457-481.
22. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50:1966;163-170.
23. Högberg T, Kågedal B. Long-term follow-up of ovarian cancer with monthly determinations of serum CA 125. Gynecol Oncol. 46:1992;191-198.
24. Autio-Harmainen H, Karttunen T, Hurskainen T. Expression of 72 kDa type IV collagenase (gelatinase A) in benign and malignant ovarian tumors. Lab Invest. 63:1993;312-321.
25. Afzal S, Lalani E-N, Foulkes W D, Boyce B, Tickle S, Cardillo M R, Baker T, Pignatelli M, Stamp G WH. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab Invest. 74:1996;406-421.
26. Stearns M E, Wang M. Type IV collagenase (Mr 72,000) expression in human prostate: benign and malignant tissue. Cancer Res. 53:1993;878-883.
27. Boag A H, Young I D. Immunohistochemical analysis of type IV collagenase expression in prostatic hyperplasia and adenocarcinoma. Mod Pathol. 6:1993;65-68.
28. Soini Y, Hurskainen T, Höyhtyä M, Oikarinen A, Autio-Harmainen H. 72KD and 92 KD type IV collagenase, type IV collagen and laminin mRNAs in breast cancer: a study by in situ hybridization. J Histochem Cytochem. 42:1994;945-951.
29. Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y. Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res. 87:1996;602-611.
30. Nomura H, Fujimoto N, Seiki M, Mai M, Okada Y. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinoma. Int J Cancer. 69:1996;9-16.
31. Schoedel K E, Greco M A, Stetler-Stevenson W G, Ohori N P, Oswami S, Present D, Steiner G C. Expression of metalloproteinases and tissue inhibitors of metalloproteinases in giant cell tumor of bone: an immunohistochemical study with clinical correlation. Hum Pathol. 27:1996;1144-1148.
32. Montironi R, Fabris G, Lucarini G, Biagini G. Location of 72-kd metalloproteinase (type IV collagenase) in untreated prostatic adenocarcinoma. Pathol Res Pract. 191:1995;1140-1146.
33. Soini Y, Pääkkö P, Autio-Harmainen H. Genes of laminin B1 chain, α1(IV) chain of type IV collagen and 72-kD type IV collagenase are mainly expressed by the stromal cells of lung carcinomas. Am J Pathol. 142:1993;1622-1630.
34. Gress T M, Muller-Pillasch F, Lerch M M, Friess H, Buchler M, Adler G. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer. 62:1995;407-413.
35. Miyajima Y, Nakano R, Morimatsu M. Analysis of expression of matrix metalloproteinases-2 and -9 in hypopharyngeal squamous cell carcinoma by in situ hybridization. Ann Otol Rhinol Laryngol. 104:1995;678-684.
36. Terada T, Okada Y, Nakanuma Y. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human livers and primary liver tumor. Hepatology. 23:1996;1341-1344.
37. Charous S J, Stricklin G P, Nanney L B, Netterville J L, Burkey B B. Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in head and neck squamous cell carcinoma. Ann Otol Rhinol Laryngol. 106:1997;271-278.
38. De Nictolis M, Garbisa S, Lucarini G, Goteri G, Masiero L, Ciavattini A, Garzetti G G, Stetler-Stevenson W G, Fabris G, Biagini G, Prat J. 72-kilodalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors or the ovary: a clinicopathologic, immunohistochemical, and serological study. Int J Gynecol Pathol. 15:1996;102-109.